Navigation Links
By 2018, GlaxoSmithKline's Votrient Will Garner Sales of $640 Million and Will Overtake Pfizer's Sutent as the Renal Cell Carcinoma Market Leader
Date:9/14/2009

WALTHAM, Mass., Sept.14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.

The new Pharmacor report entitled Renal Cell Carcinoma finds that Votrient will overtake Sutent as the renal cell carcinoma market leader by 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. For the treatment of renal cell carcinoma, Votrient is expected to launch in the U.S. in 2010, in Europe in 2011 and in Japan in 2012. According to the report, the angiogenesis inhibitor drug class will continue to dominate this market over the next decade, capturing 87 percent of total sales in 2018.

The report also finds that Novartis's Afinitor and Pfizer's axitinib will surpass Bayer Healthcare/Onyx's Nexavar and Wyeth's Torisel by 2018 in the second- and third-line treatment settings. In 2008, Nexavar was the leading therapy in the second-line setting and Torisel was the leading therapy in the third-line setting for the treatment of renal cell carcinoma.

"Thought leaders we interviewed indicate that they are optimistic about several emerging therapies, most notably axitinib and Votrient," said Decision Resources Analyst Karen Pomeranz, M.Sc., Ph.D. "One expert called axitinib 'the most exciting' emerging agent in renal cell carcinoma in recent years and another thought leader said that Votrient's clinical efficacy is comparable to that of Sutent and that Votrient has a more favorable side-effect profile than Sutent."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources         Decision Resources, Inc.
    Christopher Comfort        Elizabeth Marshall
    781-296-2597               781-296-2563
    ccomfort@dresources.com    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award
2. CyberKnife Center of Miami Executive Director James G. Schwade M.D. Garners Ultimate Miami CEO Award
3. AST Leaders Fly to Capitol Hill to Garner and Secure Support for Transplantation Initiatives
4. Tray-Pak Direct Mailer Garners 21% Response, Design Award
5. Absolutely PR's Maggie Holben Participates In CBSA BioBreakfast Expert Panel "How to Garner Media Attention & Effectively Use Public Relations Tactics"
6. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
7. Novel IBS treatment developed at UB garners $8.5 million for seven-year clinical trial
8. Performance Health Technologies Garners Additional Media Coverage, Including Scientific Americans News Blog
9. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
10. Rising Garners Top Honors on the Private Company Indexs Top Five Growth Companies List for Q1 2008
11. Study garners unique mating photos of wild gorillas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., ... for adherence to the highest standards of trauma, maternity, cancer and chronic obstructive ... president and CEO, Dr. Daniel Messina. , Among the recognitions, the American College ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
(Date:12/8/2016)... Rock, AR (PRWEB) , ... December 08, 2016 ... ... providing insurance and financial planning services from offices headquartered in Little Rock, has ... Food Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey ... to residential and commercial clients in the northern Alabama and Georgia regions, is ... , Since 1977, Nobis Works has built a network of support and education ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX , ... Nationwide Children,s Hospital signed a membership agreement ... the development of new cures. The ... over 57 million patients globally, biopharmaceutical companies and ... to improve protocol design, site selection, patient recruitment, ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: